Macrophage-specific IGF-1 overexpression decreases plaque MMP8 and. حسب Patricia Snarski (22305205)

Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> حسب Razia Rashid Rahil (22772495)

Effects of GJE extract treatment decreased accumulation of Col1a1. حسب Natnicha Suttawong (22367172)

Evogliptin attenuates the pyroptotic cell death of VSMCs during CER treatment by decreasing the pyroptotic-associated genes and GSDM-D cleavage efficiency <i>in-vitro.</i> حسب Razia Rashid Rahil (22772495)

"…<p>(A) Bar graph showed EVO significantly decreased Lactate dehydrogenase (LDH) release in CER treated P_i‐induced VSMCs. …"

A summary of the included study characteristics. حسب Zahra Tajik (20752452)

"…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"

The significant decrease in GLT-1 levels observed in the nucleus accumbens of rats that had consumed morphine for fifty-six days was completely reversed by the co-administration of... حسب María Elena Quintanilla (8068691)

Overview of the six original ACTIV-3/TICO trials. حسب Elizabeth S. Munroe (21568166)

<i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages. حسب Justine Guguin (9088672)

Conditional ablation of <i>Ybx1</i> leads to a reduction in cortical progenitor cell pool and a decrease in cortical thickness. حسب Jian Zhang (1682)

Group-level narrow- and broad-band spectral changes after hemispherotomy reveal a marked EEG slowing of the isolated cortex, robust across patients. حسب Michele Angelo Colombo (22446342)

PDRN decreases the expression of cellular aging markers. حسب Jingjing Chen (293564)

Colocalization of the peroxisomal marker PEX14p with amelogenin, pancytokeratin and vimentin. حسب Claudia Colasante (101665)

Narrow- and broad-band spectral changes after hemispherotomy in an awake representative patient, displaying marked electroencephalography (EEG) slowing of the isolated cortex. حسب Michele Angelo Colombo (22446342)

Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. حسب Søren Egstrand (10906087)

A flow diagram of the study entry. حسب Sakiko Fukui (387048)

"…We created a time-series dataset for 69 participants, documenting their average weekly food intake (on a scale of 0-10). …"

Data from: Colony losses of stingless bees increase in agricultural areas, but decrease in forested areas حسب Malena Sibaja Leyton (18400983)

"…On average, meliponiculturists lost 43.4 % of their stingless bee colonies annually, 33.3 % during the rainy season, and 22.0 % during the dry season. We found that colony losses during the rainy season decreased with higher abundance of forested areas and increased with higher abundance of agricultural area around meliponaries. …"

Validation of genetic markers for risk of OA or knee OA for decrease in minJSW. حسب Mieke L. M. Bentvelzen (21594442)

List of Included studies. حسب Zahra Tajik (20752452)

"…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"

The search strategy in three databases. حسب Zahra Tajik (20752452)

"…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"

NIH score. حسب Zahra Tajik (20752452)

"…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"